Purpose
To assess the APTw-MRI features of isocitrate dehydrogenase (IDH)-wildtype and IDH-mutant grade-II gliomas and to test the hypothesis that the APTw signal is a surrogate imaging marker for identifying IDH mutation status preoperatively.
Methods
27 patients with pathologically confirmed low-grade glioma, who were previously scanned at 3T, were retrospectively analyzed. The Mann-Whitney test was used to evaluate relationships between APTw intensities for IDH-mutant and IDH-wildtype groups, and the receiver-operator-characteristic analysis was used to assess the diagnostic performance of APTw.
Results
Based on histopathology and molecular analysis, seven cases were diagnosed as IDH-wildtype grade-II gliomas, and 20 cases as IDH-mutant grade-II gliomas. The maximum and minimum APTw values, based on multiple regions of interest, as well as the whole-tumor histogram-based mean and 50th percentile APTw values, were significantly higher in the IDH-wildtype gliomas than in the IDH-mutant groups. This corresponded to the areas under the receiver-operator-characteristic curves of 0.89, 0.76, 0.75, and 0.75, respectively, for the prediction of the IDH mutation status.
Conclusions
IDH-wildtype lesions were typically associated with relatively high APTw signal intensities, compared with IDH-mutant lesions. The APTw signal could be a valuable imaging biomarker by which to identify IDH1 mutation status in grade-II gliomas.
Objectives
To show the ability of using the amide-proton-transfer-weighted (APTW) MRI signals as imaging biomarkers to differentiate primary central-nervous-system lymphomas (PCNSLs) from high-grade gliomas (HGGs).
Methods
Eleven patients with lymphomas and 21 patients with HGGs were examined. Magnetization-transfer (MT) spectra over an offset range of ±6 ppm and the conventional MT ratio (MTR) at 15.6 ppm were acquired. The APTW signals, total chemical-exchange-saturation-transfer signal (integral between 0 and 5 ppm, CESTtotal), and MTR signal were obtained and compared between PCNSLs and HGGs. The diagnostic performance was assessed with the receiver-operating-characteristic-curve analysis.
Results
The PCNSLs usually showed more homogeneous APTW hyperintensity (spatially compared to the normal brain tissue) than the HGGs. The APTWmax, APTWmax-min, and CESTtotal signal intensities were significantly lower (P < 0.05, 0.001, and 0.05, respectively), while the APTWmin and MTR were significantly higher (both P < 0.01) in PCNSL lesions than in HGG lesions. The APTW values in peritumoral oedema were significantly lower for PCNSLs than for HGGs (P < 0.01). APTWmax-min had the highest area under the receiver-operating-characteristic curve (0.963) and accuracy (94.1%) in differentiating PCNSLs from HGGs.
Conclusions
The protein-based APTW signal would be a valuable MRI biomarker by which to identify PCNSLs and HGGs presurgically.
Background
To investigate the effect of a social media platform for the treatment of Helicobacter pylori infection.
Materials and Methods
We enrolled 222 patients from October 2018 to June 2019, who required H pylori therapy. We used WeChat, a social media platform, as a patient reminder tool. They were randomly divided into the intervention and control groups (n = 111 per group) to compare and evaluate their disease awareness, medication adherence, incidence of adverse drug reactions, and H pylori eradication rate.
Results
Patients in the intervention group had significantly better disease‐related knowledge, medication adherence, and H pylori eradication rates than those in the control group (P < .05).
Conclusions
Using a social media platform may improve treatment rates of H pylori infection.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.